As a newly emerging and extensively studied pathway, iron dysregulation is activated early in AD pathogenesis and exhibits substantial cross-talk with classical pathological features such as Aβ deposition and tau hyperphosphorylation—rendering it a promising target for biomarker development. Here, MAPT is linked to Alzheimer disease.